Thursday, March 21, 2019
8:00 am – 12:00 pm
Free for RWC Main Program Attendees!


The RWC Unplugged program offers a unique opportunity to learn, share and discuss controversial topics in retina with industry experts and clinical leaders – with no scripts or industry commercials. Join your colleagues and together we'll delve into unfiltered dialogue relating to some of the most controversial topics in retina.

You'll benefit from participating in the following conversations:

  • Who to watch
  • Candid dialogue on the most highly debated topics in retina
  • Panel discussions with top KOLs
  • Roadmap for future developments
  • Regulatory policy
  • Business development
  • Groundbreaking technology
  • Financial opportunities


Neovasular AMD

  • The Impending Anti-VEGF War
  • Panel Discussion – Biosimilars: Will They Have an Impact?
  • The TIE2 Pathway Real or Fake News?
  • Combination Drugs


  • Complement Inhibition: Real News or Fake News?
  • Other Pathways in Development


  • Anti-VEGF Drugs: Ranibizumab vs. Aflibercept vs. Bevacizumab vs. Conbercept vs. Brolucizumab vs. Abicipar Pegol
  • New Target Drugs

Investor Perspective

Large Company Strategic Perspective

Small Company/Start-up Perspective

FDA Perspective

Please note: RWC Unplugged is not approved for AMA PRA Category 1 Credit(s)™.